Navigation Links
Harnessing anticancer drugs for the future fight against influenza
Date:9/5/2012

Medical Systems Virology group at the Institute for Molecular Medicine Finland (FIMM) at the University of Helsinki, together with its national and international collaborators, developed a new cell screening method that can be used to identify potential anti-influenza drugs. The researchers were able to identify two novel compounds with anti-influenza activity, obatoclax and gemcitabine and prove the efficacy of a previously known drug saliphenylhalamide.

The study was recently accepted for publication in the Journal of Biological Chemistry and is now available online.

Influenza viruses cause significant human morbidity and mortality. To treat the infections, different virus-directed drugs have been developed. However, the currently available drugs are targeting viral proteins and due to a high mutation rate the influenza viruses quickly develop resistance to them. For that reason, next-generation antiviral drugs should be directed towards the host functions. The results of this study provide a foundation for development of next-generation antiviral drugs. Furthermore, these identified compounds can be used as chemical tools when studying the molecular mechanisms of virus-host interactions.

"An interesting aspect of this study is that the antiviral effects of obatoclax, saliphenylhalamide and gemcitabine, which all are either investigational or approved anticancer agents, are achieved at much lower concentrations than that needed to mediate cancer cell death" said the group leader Denis Kainov.

However, further research is still needed before these drugs can be clinically tested and applied in influenza infections.

This research project is a good example of repurposing of drugs, i.e. finding new applications for existing drugs and thus saving money and time on drug development.

"We anticipate that these types of drugs could in the future reinforce the therapeutic arsenal and address the need
'/>"/>

Contact: Dr. Laura Kakkola
laura.kakkola@fimm.fi
358-503-112-552
University of Helsinki
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Harnessing the Materials Genome Conference
2. A new vision for harnessing data about life on Earth
3. High levels of TRAIL protein in breast milk might contribute to anticancer activity
4. Chemicals today, drugs tomorrow: U-Ms new Center for Drug Discovery
5. Target for potent first-strike influenza drugs identified
6. 3-D motion of cold virus offers hope for improved drugs using Australias fastest supercomputer
7. Single protein promotes resistance to widely used anti-estrogen drugs
8. Efforts to develop new drugs that hopefully will never be used
9. Arsenic for better drugs and cleaner crops
10. MIT-designed cooler preserves tuberculosis drugs, records doses
11. La Jolla Institute discovery could lead to new way to screen drugs for adverse reactions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Harnessing anticancer drugs for the future fight against influenza
(Date:10/22/2014)... -- Aware, Inc. (NASDAQ: AWRE ), a leading ... for its third quarter ended September 30, 2014. ... an increase of 40% compared to $4.3 million in the ... of 2014 was $4.1 million compared to $1.0 million in ... current three month period was primarily due to: i) a ...
(Date:10/18/2014)... a sample of patients with undiagnosed, suspected genetic conditions, ... with a higher molecular diagnostic yield than traditional molecular ... JAMA . The study is being released to coincide ... , Exome sequencing, which sequences the protein­coding region of ... material present in a cell or organism), has been ...
(Date:10/17/2014)... German . To ... treating overdoses, doctors are often limited to supportive therapy such ... a combination of drugs involved. So what can be done ... pills? ETH professor Jean-Christophe Leroux from the Institute of Pharmaceutical ... this question. "The task was to develop an agent that ...
Breaking Biology News(10 mins):Aware, Inc. Reports Third Quarter 2014 Financial Results 2Aware, Inc. Reports Third Quarter 2014 Financial Results 3Aware, Inc. Reports Third Quarter 2014 Financial Results 4Aware, Inc. Reports Third Quarter 2014 Financial Results 5Aware, Inc. Reports Third Quarter 2014 Financial Results 6Aware, Inc. Reports Third Quarter 2014 Financial Results 7Study examines type of exome sequencing and molecular diagnostic yield 2Study examines type of exome sequencing and molecular diagnostic yield 3Emergency aid for overdoses 2Emergency aid for overdoses 3
... steelhead trout in hatcheries causes a dramatic and unexpectedly ... wild, a new Oregon State University study shows, and ... practices. The research, to be published Friday in ... the reproductive success of steelhead trout, an important salmonid ...
... is reined in prevented from giving up its ... presence of a protein modification that stifles any genes ... heart or other specialized tissue. But, thanks to the ... primed and poised, ready to develop into specialized body ...
... WHAT: The 2007 Prostate Cancer Foundation Scientific Retreat will ... prostate cancer. Presentations include discoveries expected to lead ... help men avoid developing prostate cancer. ... share new research on how eating common foods such ...
Cached Biology News:Salmonid hatcheries cause 'stunning' loss of reproduction 2Salmonid hatcheries cause 'stunning' loss of reproduction 3Human embryonic stem cells remain embryonic because of epigenetic factors 2Human embryonic stem cells remain embryonic because of epigenetic factors 3New prostate cancer research findings 2
(Date:10/22/2014)... 2014 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for its Oral Amphotericin B program.  The company ... vitro work involving samples from HIV/AIDS patients ... complete pre clinical studies and regulatory filings to ... trial, utilizing approximately $700,000 of funding and technological ...
(Date:10/22/2014)... 22, 2014 Research and Markets  has ... by Material, by Application, Geography - Global Analysis and ... Organic electronics, also called as polymer ... science which deals with small conductive molecules and electrically ... molecules and polymers are carbon based, made using synthetic ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems ... and Labeling Systems, Table-top Counters) by End-user (Inpatient ... & Trends to 2019” analyzes and studies the ... America, Europe, Asia-Pacific, and the Rest of the ... 30 figures spread through 300 pages and in-depth ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Convey ... that a team from Iowa State University won first ... contest. Using a Convey HC-2ex, the team’s solution achieved ... times faster than the second place finisher. , Experts ... embarked upon the month long challenge, using a variety ...
Breaking Biology Technology:iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 2Team from Iowa State Wins 2014 MemoCODE Design Contest Using Convey HC-2ex 3
... Interleukin Genetics,Inc. (Amex: ILI ), announced today that ... August 13, 2008, at 8:30 a.m. EDT to review ... update on,recent corporate developments., To access the live ... and replay access of the teleconference,will be available on ...
... announced today that,it has updated coverage and has issued ... INO ). "The proposed merger of Inovio and VGX,would ... deliver,therapeutic agents and positions Inovio/VGX, based on further development,progress, ... gene therapy,companies," said Ross Silver, Director of Research for ...
... Inc.,(Nasdaq: NXTM ), a leading manufacturer of ... Chief Executive Officer and Robert,Brown, Chief Financial Officer, ... Where possible, a webcast of each event will ... time of each,conference., Canaccord Adams Annual ...
Cached Biology Technology:Interleukin Genetics Announces Conference Call and Webcast to Discuss Second Quarter 2008 Business Results 2Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target 2NxStage Announces Investor Conference Schedule 2
... The Agilent One-Color RNA Spike-In Kit ... specifically anneal only to complementary control probes ... cross-hybridization. The spike-ins serve as a positive ... NOTE: This kit is a ...
... spatulas have been designed to save time ... those interested in eliminating the recycling and ... is individually packaged, RNase/DNase free, non-pyrogenic and ... new product number, created to easily match ...
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... CHEMICONs Alkaline Phosphatase Detection Kit (Catalog ... tool for the phenotypic assessment of ES ... activity. Available separately from CHEMICON are ... and TRA-2-54 (Catalog Number MAB4354), which permit ...
Biology Products: